Xiaoming Gong

Dr. Xiaoming Gong

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 October 2024 in Life
Verified
Journal Article
Open access
PDF file
XGXiaoming Gong
Xiaoming Gong
RHRichard Hertle
Richard Hertle
Inherited retinal diseases (IRDs) are a clinically and genetically diverse group of progressive degenerative disorders that can result in severe visual impairment or complete blindness. Despite their predominantly monogenic inheritance patterns, the genetic complexity of over 300 identified disease-causing genes presents a significant challenge in correlating clinical phenotypes with genotypes. Achieving a molecular diagnosis is crucial for providing patients with definitive diagnostic clarity and facilitating access to emerging gene-based therapies and ongoing clinical trials. Recent advances in next-generation sequencing technologies have markedly enhanced our ability to identify genes and genetic defects leading to IRDs, thereby propelling the development of gene-based therapies. The clinical success of voretigene neparvovec (Luxturna), the first approved retinal gene therapy for RPE65-associated Leber congenital amaurosis (LCA), has spurred considerable research and development in gene-based therapies, highlighting the importance of reviewing the current status of gene therapy for IRDs, particularly those utilizing adeno-associated virus (AAV)-based therapies. As novel disease-causing mutations continue to be discovered and more targeted gene therapies are developed, integrating these treatment opportunities into the standard care for IRD patients becomes increasingly critical. This review provides an update on the diverse phenotypic–genotypic landscape of IRDs, with a specific focus on recent advances in the understanding of IRDs in children with infantile nystagmus syndrome (INS). We highlight the complexities of the genotypic–phenotypic landscape of INS-associated IRDs, including conditions such as achromatopsia, LCA, congenital stationary night blindness, and subtypes of retinitis pigmentosa. Additionally, we provide an updated overview of AAV-based gene therapies for these diseases and discuss the potential of gene-based therapies for underlying IRDs that lead to INS, offering a valuable resource for pediatric patients potentially eligible for ongoing clinical trials.

Verified
Journal Article
Open access
PDF file
XGXiaoming Gong
Xiaoming Gong
FOFaruk Orge
Faruk Orge
Ocular diseases, including glaucoma, diabetic retinopathy (DR), and age-related macular degeneration (AMD), remain major global causes of irreversible vision loss. Despite advances in clinical management, current therapies insufficiently address the shared metabolic, inflammatory, vascular, and neurodegenerative mechanisms underlying these conditions. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), widely used for type 2 diabetes and obesity, have emerged as multi-target candidates for ocular therapeutics due to their pleiotropic anti-inflammatory, antioxidant, vasculoprotective, and neuroprotective properties. Preclinical studies consistently demonstrate that GLP-1RAs preserve blood–retina barrier integrity, suppress pathological angiogenesis, mitigate oxidative and inflammatory stress, and protect retinal neurons from degeneration. Complementary clinical and real-world evidence shows a robust and reproducible reduction in glaucoma risk among GLP-1RA users across diabetic and non-diabetic populations. By contrast, findings for DR and AMD are more heterogeneous and appear context-dependent, with potential benefits most evident in early or non-exudative disease stages. Emerging safety considerations—including reports of nonarteritic anterior ischemic optic neuropathy and early DR worsening in the setting of rapid glycemic improvement—highlight the need for careful interpretation, individualized risk assessment, and appropriate ophthalmic monitoring. This review synthesizes molecular mechanisms, experimental data, clinical and pharmacoepidemiologic evidence, and safety signals to critically evaluate the therapeutic potential of GLP-1RAs in ocular disease. We also outline key translational challenges, including the need for ocular-targeted delivery strategies, prospective ophthalmology-specific trials, and precision-medicine approaches to determine when and how GLP-1RAs can be safely advanced as disease-modifying treatments in ophthalmology.

12 January 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
XGXiaoming Gong
Xiaoming Gong
FOFaruk Orge
Faruk Orge
Ocular diseases – including glaucoma, diabetic retinopathy, and age-related macular degeneration – remain major global causes of irreversible vision loss. Despite therapeutic advances, current interventions that address the convergent metabolic, inflammatory, vascular and neurodegenerative components of these diseases are limited. Glucagon‑like peptide‑1 receptor agonists (GLP‑1RAs), widely used for type 2 diabetes and obesity, have emerged as multi-target candidates for ocular therapeutics due to their pleiotropic anti‑inflammatory, antioxidant, vasculoprotective, and neuroprotective properties. Increasing preclinical and clinical evidence indicates that GLP‑1RAs preserve blood–retina barrier integrity, inhibit pathological angiogenesis, reduce inflammation, promote antioxidant responses and protect retinal neurons from degeneration. However, rare ocular adverse events – including nonarteritic anterior ischemic optic neuropathy and “early worsening” of diabetic retinopathy – highlight the need for a balanced and comprehensive consideration of evidence. This review synthesizes mechanistic in-sights, experimental findings, clinical data, and safety considerations to critically assess the potential of GLP‑1RAs as disease‑modifying therapeutics for ocular disorders and outlines translational challenges and research priorities to guide future ophthalmology‑focused investigations.

Verified
Journal Article
Open access
PDF file
NHNancy N. Hanna
Nancy N. Hanna
DNDoris Canes Napoles
Doris Canes Napoles
AFAaron Flickinger
Aaron Flickinger
CCCarter Carlos
Carter Carlos
RHRichard Hertle
Richard Hertle
XGXiaoming Gong
Xiaoming Gong
Objectives: This study aimed to evaluate clinical characteristics and treatment outcomes in a cohort of pediatric patients with glaucoma over 10-year period at a tertiary referral center. Methods: Medical records of patients younger than 18 years diagnosed with glaucoma between 1 January 2013 and 31 December 2023 were retrospectively reviewed. Diagnoses were classified according to the Childhood Glaucoma Research Network (CGRN). Demographic data, clinical characteristics and surgical outcomes were analyzed. Statistical analyses included Student’s t-test, one-way ANOVA, and corresponding non-parametric methods (α = 0.05). Results: A total of 105 patients (168 eyes) were included, with a mean age of 5.52 ± 5.61 years, and a mean duration of follow-up of 5.41 ± 3.37 years. Mean baseline intraocular pressure (IOP) was 24.41 ± 10.85 mmHg. Secondary glaucoma was the predominant category (69%), led by glaucoma following cataract surgery (26%). Bilateral disease occurred in 60% of cases, more frequently in secondary forms. Surgery was performed in 57.4% of glaucomatous eyes. All subtypes except glaucoma following cataract surgery (GFCS) achieved significant reductions in IOP from baseline (p < 0.01). Despite effective IOP control, final visual acuity remained limited in many patients, especially those with glaucoma associated with non-acquired ocular anomalies or following cataract surgery. Worse baseline vision and higher presenting IOP were associated with poorer final acuity. Conclusions: Secondary glaucoma, particularly GFCS, was the most common form of pediatric glaucoma in this cohort. Although IOP control was generally successful, visual outcomes frequently remained suboptimal, highlighting the importance of early detection, comprehensive management, and close long-term monitoring.

17 March 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
NHNancy N. Hanna
Nancy N. Hanna
DNDoris Canes Napoles
Doris Canes Napoles
AFAaron Flickinger
Aaron Flickinger
CCCarter Carlos
Carter Carlos
RHRichard Hertle
Richard Hertle
XGXiaoming Gong
Xiaoming Gong
Objectives: This study aimed to evaluate clinical characteristics and treatment outcomes in a cohort of pediatric patients with glaucoma over 10-year period at a tertiary referral center. Methods: Medical records of patients younger than 18 years diagnosed with glaucoma between January 1, 2013, and December 31, 2023, were reviewed. Diagnoses were classified according to the Childhood Glaucoma Research Network (CGRN). Demographic, clinical characteristics and surgical outcomes were analyzed. Statistical analyses included Student’s t-test, one‑way ANOVA, and corresponding non-parametric methods (α = 0.05). Results: A total of 105 patients (168 eyes) were included, with a mean age of 5.52 ± 5.61 years, and a mean duration follow-up of 5.41 ± 3.37 years. Mean baseline intraocular pressure (IOP) was 24.41 ± 10.85 mmHg. Secondary glaucoma was the predominant category (69%), led by glaucoma following cataract surgery (26%). Bilateral disease occurred in 60% of cases, more frequently in secondary forms. Surgery was performed in 57.4% of glaucomatous eyes. All subtypes except glaucoma following cataract surgery (GFCS) achieved significant reductions in IOP from baseline (P < 0.01). Despite effective IOP control, final visual acuity remained limited in many patients, especially those with glaucoma associated with non‑acquired ocular anomalies or following cataract surgery. Worse baseline vision and higher presenting IOP were associated with poorer final acuity. Conclusions: Secondary glaucoma, particularly GFCS, was the most common form of pediatric glaucoma in this cohort. Although IOP control was generally successful, visual outcomes frequently remained suboptimal, highlighting the importance of early detection, comprehensive management, and close long‑term monitoring for children at risk.